News - TOSP

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics

01 Feb 2023

Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials. The collaboration aims to accelerate Endevica’s... Read more

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board

01 Feb 2023

Scancell Holdings Plc (“Scancell” or the “Company”) Directorate Change Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board Jean-Michel brings 25 years of experience in the international pharmaceutical and biotech industries both in an executive and non-executive capacity Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today... Read more

Ellison Institute Submits Planning Application for Oxford Campus

30 Jan 2023

The new science research facility’s purposeful design promotes collaboration and interdisciplinary research, incorporating laboratories, a patient clinic, and educational spaces, with exemplar Environmental, Social, & Governance credentials at its heart Oxford, UK – 30 January 2023 – The Lawrence J. Ellison Institute for Transformative Medicine submitted a planning application to Oxford City Council for a new research and development facility... Read more

Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema

24 Jan 2023

OXU-001 represents potential best-in-class treatment for DME with just one, targeted administration per year Initiation of OXEYE Phase 2 clinical trial of OXU-001 in DME patients on-track for first quarter of 2023; Initial clinical data on safety and durability expected in 2023 January 24, 2023 08:00 AM Eastern Standard Time OXFORD, United Kingdom--(BUSINESS WIRE)--Oxular Limited, a clinical-stage ophthalmic company developing... Read more

First-in-human clinical data shows SonoTran® is safe and well-tolerated

23 Jan 2023

Data presented at the European Symposium on Ultrasound Contrast Imaging also demonstrated consistent SonoTran® Particle activation Recruitment underway for Delivery and Efficacy cohorts of Phase 1/2a proof of concept study Oxford, UK – 23 January 2023 – OxSonics Therapeutics, a clinical-stage medtech company focused on transforming cancer treatment through SonoTran®, its proprietary ultrasound-based drug delivery platform, today announces... Read more